Tissue transglutaminase (TG2) plays a central role in fibrosis, by recruiting TGF-β, disturbing extracellular matrix protein homeostasis and supporting fibroblast proliferation.
Zedira scientists developed a new class of tissue transglutaminase inhibitors: reversible mode-of-inhibition, potent and selective. The novel compounds were optimized for in vivo oral bioavailability and favourable pharmacokinetic profiles. We refer to the respective press release.
Proprietary drug candidates are therefore available to target dysregulated active TG2 in fibrotic disorders, of the lung, kidney, and liver.
Zedira offers partnerships for clinical development of these drug candidates.
Moreover, Zedira is planning to expand its global leadership position in the transglutaminase field by investing into follow-up drug discovery projects.
Interested? Then please do not hesitate contacting us: firstname.lastname@example.org